Healthcare providers use Bendamustine in treating patients who have chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. This drug comes in single-use vials in 100 mg to inject intravenously. The recommended dosage of Bendamustine is 100 mg/m2 administered intravenously over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Bendamustine is an alkylating agent.

Bendamustine injection 100…

Cytarabine is found in a sterile, preservative-free, purple, lyophilized cake in a single-dose vial. This medicine is used in treating patients with acute myeloid leukemia or AML with myelodysplasia-related changes. Cytarabine comes in 100 mg, 500 mg and 1000 mg for intravenous administration. One should administer this medication according to the prescription of the healthcare professional.

Cytarabine injection…

Bendamustine is an alkylating drug; it is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. This medicine comes in single-use vials for intravenous infusion in 100 mg. The active ingredient in the drug is Bendamustine hydrochloride, and the inactive ingredient is mannitol. One should take this medicine as per the prescription of the doctor. Bendamustine is used in treating chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.…

The FDA endorsed the medication Arsenic Trioxide in 2000 for treating patients experiencing intense promyelocytic leukemia who are unmanageable to or have backslid from retinoid and anthracycline chemotherapy and whose APL is portrayed by the presence of the t(15;17) movement or PML/RAR-alpha quality articulation. This medicine is provided in single-use ampoules for 10 mg/10 ml intravenous mixture.…

The FDA endorsed the medication Arsenic Trioxide in 2000 for treating patients experiencing intense promyelocytic leukemia who are unmanageable to or have backslid from retinoid and anthracycline chemotherapy and whose APL is portrayed by the presence of the t(15;17) movement or PML/RAR-alpha quality articulation. This medicine is provided in single-use ampoules for 10 mg/10 ml intravenous mixture.…

The FDA endorsed the medication Arsenic Trioxide in 2000 for treating patients experiencing intense promyelocytic leukemia who are unmanageable to or have backslid from retinoid and anthracycline chemotherapy and whose APL is portrayed by the presence of the t(15;17) movement or PML/RAR-alpha quality articulation. This medicine is provided in single-use ampoules for 10 mg/10 ml intravenous mixture.…